What I did:
Sold: 25 shares $PLTR (-0,79 %) at €153,40
Bought: 75 shares $NOVO B (-1,61 %) at €50.50
Reason:
Why $PLTR (-0,79 %) reduced?
- P/E ratio 2025: 307x - absurdly overvalued even for growth
- P/E ratio 2026: 218x - Still casino territory
- Had already sold 50% at +200% (unfortunately too early 🤦)
- I'll keep the remaining 25 shares for now.
- Risk management: Secure profits at such valuations
Why $NOVO B (-1,61 %) in?
- Healthcare exposure is missing completely in my portfolio
- GLP-1 mega-trend: Oral Wegovy performing better than expected in the US
- Timing: Stock -61% from all-time high, fundamental story intact
- Valuation: P/E ratio 17x vs. PLTR's 307x - much more rational
- Long term: 25 year horizon, ageing population = healthcare growth
Risks I see:
- Eli Lilly competition
- Trump's tariff threat on Denmark (short-term political uncertainty)
- Patent cliffs long term
- Individual stock risk instead of healthcare ETF
My thoughts:
PLTR was a 10-bagger for me, but at P/E 307x it's getting too hot for me. Better to shift some profits into fundamentally more favorable quality stocks. Novo at -64% of top + oral pill launch = interesting risk/reward with a long horizon.
What do you think - justifiable decision or mistake?
Looking forward to your opinions! 🚀
- Should I have just let PLTR continue to run?
- Is Novo too risky as a single stock (better a healthcare ETF)?
- Is the timing with Novo ok or still too early?
